Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when TRVI files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTrevi Therapeutics doubles authorized shares to 400M, adds 8M shares to equity plan
Filed June 4, 2026 · Period ending June 3, 2026 · ~1 min read
Key Changes
-
high
Shareholders approved doubling authorized common stock from 200 million to 400 million shares, effective June 3, 2026. This significantly expands the company's capacity for future capital raises, acquisitions, or employee compensation, which could dilute existing shareholders.
Item 5.03 verify on EDGAR → -
medium
Amended equity plan adds 8 million shares for employee and director stock awards, caps director compensation, and tightens share recycling rules to prevent reuse of shares used for tax withholding or option exercise.
Item 5.07 verify on EDGAR → -
low
Michael Heffernan elected as Class I director with term expiring at 2029 annual meeting. Ernst & Young ratified as independent auditor for fiscal year 2026.
Item 5.07 verify on EDGAR →
Summary
Trevi Therapeutics held its annual meeting on June 3, 2026, where shareholders approved two significant changes to the company's capital structure. The most material decision was doubling the authorized common stock from 200 million to 400 million shares, giving management substantial flexibility for future financing or strategic transactions.
While no immediate issuance was announced, this creates potential for significant shareholder dilution if the new capacity is utilized. Shareholders also approved expanding the 2019 equity incentive plan by 8 million shares while adding guardrails including director compensation limits and restrictions on share recycling. This balances the company's need to attract and retain talent against dilution concerns.
The meeting included routine matters: director Michael Heffernan's election through 2029 and auditor ratification. Retail investors should monitor upcoming SEC filings for any announcements of capital raises, acquisitions, or large equity grants that would utilize the newly authorized shares. The company's next quarterly report will provide insight into whether management plans to tap this expanded capacity in the near term.
Section-by-Section Diff
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
At the Annual Meeting, the Company’s stockholders, upon the recommendation of the Board of Directors of the Company (the “Board”), approved the Company's Amended and Restated 2019 Stock Incentive Plan (the “A&R 2019 Plan”), which amendment and restatement had previously been approved by the Board subject to stockholder approval, to (i) increase the number of shares available for issuance under the plan by 8,000,000 shares of common stock, (ii) limit non-employee director compensation, (iii) prohibit liberal share recycling by providing that shares delivered to the Company in satisfaction of an exercise price or tax withholding do not become available under the A&R 2019 Plan for future grants and (iv) clarify that any dividends or dividend equivalents paid with respect to awards under the A&R 2019 Plan are subject to the same vesting and forfeiture provisions as the award with respect to which the dividend or dividend equivalent is paid.
Stockholders approved changes to the company's equity compensation plan at the June 3, 2026 annual meeting. The plan now authorizes 8 million additional shares for employee and director stock awards, caps director compensation, and tightens share recycling rules to prevent reuse of shares used for tax withholding or option exercise. This increases potential dilution to existing shareholders but provides the company more flexibility to compensate and retain employees.
Event · Item 5.07 — Submission of Matters to a Vote of Security Holders
Annual meeting results: director elected, auditor ratified, executive pay approved, stock plan approved, authorized shares doubled to 400M.
Added in current filing · verify on EDGAR →
The A&R 2019 Plan was approved.
Shareholders approved the amended and restated 2019 equity incentive plan. This typically expands the share pool available for employee stock compensation, which can be dilutive but is standard for retaining talent.
Show 2 minor / wording changes
Added in current filing · verify on EDGAR →
Michael Heffernan was elected to the Board as a Class I director for a term expiring at the 2029 annual meeting of stockholders.
Michael Heffernan was elected as a Class I director with a three-year term through 2029. This is routine board governance with no immediate business impact disclosed.
Added in current filing · verify on EDGAR →
The appointment of Ernst & Young LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026 was ratified.
Shareholders ratified Ernst & Young as the independent auditor for 2026. This is a routine annual vote with no change in auditor, indicating continuity in financial reporting oversight.
Event · Item 9.01 — Financial Statements and Exhibits
Trevi Therapeutics filed a certificate of amendment to its charter and amended its 2019 stock incentive plan.
Added in current filing · verify on EDGAR →
Certificate of Amendment to the Restated Certificate of Incorporation, as amended, of Trevi Therapeutics, Inc.
The company filed a certificate of amendment to its restated certificate of incorporation. The 8-K does not provide details on what was amended, but charter amendments typically involve changes to authorized shares, corporate name, or governance provisions. Investors should review the attached exhibit for specifics.
Added in current filing · verify on EDGAR →
Amended and Restated 2019 Stock Incentive Plan (incorporated by reference to Appendix A to the Company’s Definitive Proxy Statement on Schedule 14A filed with the SEC on April 21, 2026).
The company amended and restated its 2019 stock incentive plan. The details are incorporated by reference from the April 21, 2026 proxy statement. Amendments to equity plans often involve increasing share reserves, modifying vesting terms, or adjusting eligibility, which can affect shareholder dilution.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 5, 2026 · How we verify